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Simultaneous primary cancer:
Atypical Lynch syndrome?
Cánceres primarios simultáneos; ¿síndrome de
Lynch atípico?
Lynch  syndrome  is  the  most  common  hereditary  colorectal
syndrome.  It  is  an  autosomal  dominant  disease  caused  by
germline  mutations  in  these  DNA  mismatch  repair  (MMR)
genes:1,2 MLH1  (50%),  MSH2  (40%),  MSH6  (7-10%),  and  PMS2
(5%).  The  inactivation  of  both  alleles  in  one  of  the  MMR  genes
generates  microsatellite  instability,  which  is  characteristic
of  Lynch  syndrome.1 Mutations  in  MLH1  are  associated  with
a  higher  prevalence  of  colorectal  cancer  and  mutations  inF
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oMSH2  with  extracolonic  presentation.2
Colorectal  cancer  is  the  most  frequent  neoplasia  in  this
syndrome,  followed  by  endometrial  cancer.3 Patient  age  for
colorectal  cancer  depends  on  the  mutated  MMR  gene;  MLH1
and  MLH2  are  related  to  earlier  age  presentation  (27-46
years),  and  PMS2  to  later  age  presentation  (61  years).4 Other
tumors  forming  part  of  the  Lynch  syndrome  spectrum  are:
gastric  cancer,  ovarian,  small  bowel,  urinary  tract,  hepato-
biliary,  and  brain  tumors.5 The  most  widely  used  screening
methods  are:  immunohistochemistry  and  PCR  detection  of
microsatellite  instability.  Gene  sequencing  is  required  for
the  deﬁnitive  diagnosis.6
A  52-year-old  woman  had  a  past  history  of  cancer  in
maternal  second-degree  relatives:  an  aunt  with  breast  can-
cer,  an  uncle  with  bladder  cancer,  an  aunt  with  lung  cancer,
and  an  uncle  with  esophageal  cancer,  none  of  whom  were
diagnosed  before  the  age  of  40  years.
Our  patient  had  disease  onset  with  transvaginal  bleed-
ing.  A  pelvic  ultrasound  study  and  endometrial  biopsy  were
ordered,  and  the  biopsy  reported  endometrioid  adenocar-
cinoma.  Extended  studies  showed  a  BIRADS-V  lesion  in  the
right  breast  and  a  CAT  scan  identiﬁed  a  nodule  in  the  tail  of
the  pancreas  (ﬁg.  1)  that  was  biopsied  through  endoscopic
ultrasound,  reporting  carcinoma.  CA-125  determination  was
carried  out  and  resulted  in  18  U/ml.  Radical  hysterectomy
with  pelvic  lymph  node  dissection  was  performed  and  the
histopathologic  study  reported  well-differentiated  stage  1
endometrioid  adenocarcinoma  that  was  positive  for  cyto-
keratin  5/6,  protein  16,  and  for  estrogen  and  progesterone
receptors.  Quadrantectomy  and  axillary  dissection  reported
luminal  B,  grade  II  invasive  ductal  carcinoma  that  was  HER2-
negative  and  13  out  of  28  lymph  nodes  had  metastasis.  Three
weeks  later,  the  patient  underwent  distal  pancreatectomy
with  splenectomy  that  revealed  ductal  carcinoma  of  1.3  cm
(ﬁg.  2),  with  negative  lymph  nodes.  Immunohistochemistry
of  the  latter  was  suggestive  of  mutation  in  the  MMR  genes:
MLH1  (-),  PMS2  (-),  MSH2  (+),  and  MSH6  (+).  Panendoscopy
and  colonoscopy  were  normal.  The  patient  is  currently  in
treatment  with  adjuvant  chemotherapy.
The  present  case  involves  3  primary  tumors  with  immuno-
histochemistry  suggestive  of  Lynch  syndrome.  However,  the
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2igure  1  Abdominal  CAT  scan  with  oral  and  iv  contrast.
he tip  of  the  arrow  points  to  a  round,  hyperdense,  contrast-
nhanced  lesion  adjacent  to  the  antimesenteric  edge  of  the
istal duodenum.
bsence  of  colon  cancer  and  the  presence  of  breast  cancer
re  inconsistent  with  this  syndrome.  Forty  to  60%  of  women
ith  Lynch  syndrome  may  present  with  endometrial  can-
er,  and  the  most  frequent  histologic  type  is  endometrioid.7
he  absence  of  MLH1  in  the  immunohistochemistry  sug-
ests  a  mutation  in  that  gene  that  is  affected  in  24-40%
f  the  cases  of  endometrial  cancer.7 MLH1  mutation  is
ssociated  with  disease  appearance  at  early  ages  and  a  pre-
ominance  of  colorectal  cancer,  therefore  ﬁndings  during
olonoscopy  suggestive  of  cancer  in  this  patient  would  have
een  expected.2,4
Cancer  of  the  pancreas  is  less  frequent,  compared  with
ther  associated  tumors,  and  its  presentation  age  ﬂuctuates
etween  63  and  65  years.4 The  association  of  breast  cancer
nd  cancer  of  the  pancreas  with  BRCA  2  mutation  carriers
as  been  reported,8 but  our  patient  did  not  have  a  history
f  early  age  breast  cancer  or  ovarian  cancer  in  her  familyigure  2  The  surgical  specimen  from  the  distal  pancreatec-
omy with  splenectomy.  The  tip  of  the  arrow  points  to  a  2.8  x
.1 cm  lesion  toward  the  tail  of  the  pancreas.
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and  that  mutation  has  not  been  associated  with  endome-
trial  cancer.  The  inclusion  of  breast  cancer  within  the  Lynch
syndrome  tumor  spectrum  is  still  a  subject  of  debate  and
is  presently  being  studied.9 There  is  evidence  that  muta-
tions  in  the  MLH1  gene  increase  the  risk  for  presenting  with
breast  cancer  and  the  presence  of  microsatellite  instability
is  related  to  early  age  presentation  of  that  disease.4,10
The  present  case  suggests  an  atypical  presentation  of
Lynch  syndrome.  Because  of  the  immunohistochemistry  ﬁnd-
ings,  sequencing  of  the  MLH1  gene  is  required  for  making
the  deﬁnitive  diagnosis.  However,  access  to  this  diagnostic
test  is  limited  in  Mexico  and  it  is  expensive.  Therefore,  the
patient  will  continue  with  yearly  follow-up  due  to  her  high
risk  for  developing  colorectal  cancer.
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